OncoVEX GM-CSF: Phase III started

BioVex began an open-label, international Phase III trial to compare intratumoral OncoVEX (GM-CSF) vs. subcutaneous GM-CSF given once every 2 weeks in 360 treatment-experienced patients with unresecta...